Therefore, a phase I clinical trial was initiated in which GPC3-7-19 CAR T cells showed good safety and anti-tumour efficacy in patients with hepatocellular carcinoma (HCC) [125]. Here, GPC3 is linked to hepatocellular carcinoma.